Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium; and AtriClamp, a clip designed to close the left atrial appendage to minimize the risk of stroke in patients with atrial fibrillation. It also provides MiniMax, an ablation-mapping catheter used for detecting intracardiac electrophysiological signals, creating a 3D map of the heart, and performing intracardiac irrigated RF ablation to treat arrhythmias caused by abnormalities in the heart's conduction system; and EP Bioptom, an electrode for endomyocardial biopsy using 3D mapping enabling simultaneous biopsy and creation of a three-dimensional heart map. The company was founded in 2012 and is headquartered in Warsaw, Poland.
Frequently asked questions
What sector does Medinice S.A (ICE) operate in?
Medinice S.A belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Medinice S.A (ICE) current stock price?
As of the latest data, Medinice S.A stock price is PLN 73.80, with a previous close of PLN 76.00. Medinice S.A lost -PLN 2.20 in the last trading session, representing a -2.89% loss.
What is Medinice S.A (ICE) current market capitalization?
Medinice S.A market cap is approximately 685.35 million.
What is Medinice S.A (ICE) Earnings Per Share (EPS)?
The trailing EPS is -PLN 0.82.
Does Medinice S.A (ICE) pay dividends?
No. Medinice S.A does not pay a dividend.
What is Medinice S.A (ICE) beta (volatility) score?
Medinice S.A has a beta of 1.115, meaning its volatility is roughly in line with the market.
